The clinical and pathologic features of 18 consecutive patients with peripartum cardiomyopathy at The Johns Hopkins Hospital were examined in an attempt to define the incidence of myocarditis and to determine its response to immunosuppressive agents. In addition to routine studies, patients were evaluated with echocardiography, nuclear ventriculography, right heart catheterization, and myocardial biopsy. Fourteen of the 18 patients (78%) showed evidence of myocarditis. Of these, 10 were treated with immunosuppressive therapy. Nine of the 10 treated patients with myocarditis had subjective and objective improvement. Follow-up endomyocardial biopsies in these patients showed resolution or substantial improvement in myocarditis. Four patients with myocarditis not treated with immunosuppressives also improved. All patients improving spontaneously presented with congestive heart failure within 1 month of delivery and improved dramatically within days of presentation. Four of the 18 patients showed no evidence of myocarditis. Of these, two improved, and two deteriorated (both requiring cardiac transplantation). None of these four patients were treated with immunosuppressive therapy. We conclude that in patients with peripartum cardiomyopathy, 1) the etiology remains unclear although myocarditis was present in 78% of those with this condition, 2) resolution of myocarditis is associated with significant improvement in left ventricular function, 3) myocarditis may resolve spontaneously without detectable loss of cardiac function, and 4) immunosuppressive therapy in patients with myocarditis and persistent left ventricular dysfunction may improve left ventricular function and prognosis. (Circulation 1990;81:922-928) 
T he onset of unexplained dilated cardiomyopathy occurring for the first time during the last month of pregnancy or within 5 months after delivery has been termed peripartum cardiomyopathy.' The disorder is rare, occurring approximately once in every 2,500 deliveries'-3 and comprises less than 1% of pregnancy-associated cardiovascular abnormalities. The diagnosis is considered only when other causes of left ventricular dysfunction have been See p 1154 excluded. Although viral infections, nutritional deficiencies, small coronary vessel abnormalities, hormonal changes, and immunologic responses to fetal and myometrial antigens all have been suggested as possible causes, the etiology of peripartum cardiomyopathy remains unknown. [2] [3] [4] [5] [6] While some reports of peripartum cardiomyopathy have shown that diffuse myocarditis is a concomitant feature,7 the results are equivocal as other studies have shown only cellular degeneration and fibrosis.8 Virus-induced myocarditis can result in a dilated hypofunctional heart in animals and is suspected to cause a dilated cardiomyopathy in humans.9 Circumstantial evidence suggests that treatment of endomyocardial biopsy documented myocarditis with immunosuppressive agents may improve ventricular function and prognosis.4'10 However, the performance of endomyocardial biopsy and the use of immunosuppressive drugs is not without risk, particularly in the subgroup of patients who develop myocarditis during the peripartum period. Additionally, it is not clear whether myocarditis seen in patients with peripartum cardiomyopathy portends the same prognosis as that associated with postviral or drug-induced myocarditis.
In this study, we report our experience with 18 consecutive patients with peripartum cardiomyopathy. The purpose of this investigation was to determine the incidence of myocarditis in peripartum cardiomyopathy, to characterize the hemodynamic and echocardiographic abnormalities associated with this disorder, and to evaluate the response of peripartum cardiomyopathy associated with myocarditis to immunosuppressive therapy.
Methods
From June 1983 through March 1988, 18 patients were evaluated at The Johns Hopkins Hospital for peripartum cardiomyopathy. Initial evaluation consisted of history and physical examination, routine chemistry and hematologic assessment, electrocardiogram, and chest radiograph. Serologic tests for thyroid function, ferritin, and collagen vascular disease were performed, and urinary metanephrines were measured in all patients. Noninvasive evaluation of ventricular function included two-dimensional echocardiography in all patients and nuclear ventriculography.
Endomyocardial Biopsy
At least four biopsy specimens were obtained from the right ventricular portion of the interventricular septum during serial insertions of a modified 50 cm. Stanford-Caves bioptome through the right internal jugular vein. Specimens were immediately placed in buffered 10% formalin, and one block of this tissue was prepared for light microscopy (five sections of at least four biopsy fragments per slide, four slides per specimen). Specimens for light microscopy were stained with hematoxylin and eosin. The specimens were initially classified as to the presence or absence of myocarditis. The biopsies were subsequently classified according to criteria recommended by a group of pathologists meeting in Dallas in March 1984 -the "Dallas criteria." '11 Two separate classifications are used for the first and subsequent biopsies. On the first biopsy, "active myocarditis" is defined by myocyte necrosis, degeneration, or both associated with an inflammatory infiltrate adjacent to the degenerating or necrotic myocytes. "Borderline myocarditis" is diagnosed when the inflammatory infiltrate is too sparse or when damage to myocytes is not demonstrable. "No myocarditis" implies that the myocardium either is entirely normal or shows nonspecific changes.
On subsequent biopsies, "ongoing myocarditis" means that myocyte damage or necrosis in association with an inflammatory infiltrate persists. In "resolving myocarditis," the inflammatory infiltrate is substantially reduced and is not intimately associated with necrotic myocytes. An inflammatory infiltrate is absent in "resolved myocarditis." All patients were treated with a diuretic and lowdose digoxin, while some received afterload reduction. No significant changes were made in the therapeutic regimen after the initiation of immunosuppressive therapy. Immunosuppressive therapy consisted of oral prednisone (1 mg/kg/day) and azathioprine (1.5 mg/ kg/day) for 6-8 weeks; after repeat noninvasive and invasive evaluation, immunosuppressive therapy was tapered over an additional 6-8 weeks.
Results
The clinical features of presence or absence of myocarditis on biopsy use of immunosuppressive agents, and clinical outcome of the 18 patients is shown in Table 1 . The mean age of the patients was 28±1 years. Eleven of the patients were multiparous. All patients presented after delivery; the average time from delivery to the onset of symptoms was 34+7 days and did not differ significantly between the 14 patients with myocarditis and the four without. Patients presented in severe heart failure -New York Heart Association functional class III or IV (mean cardiac index, 2.1+0.7 l/min/M2; mean echocardiographic diastolic dimension, 6.2+0.8 cm; and mean ejection fraction by gated blood pool scan, 22+7%).
Patients underwent endomyocardial biopsy as soon as possible after the diagnosis of peripartum cardiomyopathy was made. The mean time from the onset of symptoms until the time of endomyocardial biopsy was 33±9 days (range, 3-169 days) and was not significantly different between the group with and the group without myocarditis.
Myocarditis was present in 14 of the 18 patients presenting with peripartum cardiomyopathy. Patients with and without myocarditis did not differ with regard to age, multiparity, time from delivery to biopsy, or the objective measures of cardiac function (Table 1) . Nine patients were caucasian, and nine were black. No patient had evidence of nutritional deficiency; average weight was 129.8 lb (range, 98-195 lb), and four patients weighed more than 150 lb. No twin or multiple-birth deliveries occurred in this group. Three patients delivered by cesarian section.
Two patients had eclampsia. At the time of biopsy, average systolic blood pressure was 117 mm Hg (range, 80-139 mm Hg) and mean diastolic pressure was 79 mm Hg (60-96 mm Hg). The results of pathologic study of the biopsies are given in Table 2 .
Of the 14 patients with myocarditis, 10 were treated with immunosuppressive therapy. The clinical conditions of nine of these 10 treated patients improved. One of the treated patients died despite the completion of a standard immunosuppressive course of treatment. The four patients with myocarditis not treated with immunosuppressives showed significant clinical improvement with supportive therapy alone. The time from delivery to biopsy was only 10.5 days (range, 6-21 days) in the myocarditis patients demonstrating spontaneous improvement compared with 92±18 days (range, 51-195 days) for those treated with immunosuppressive therapy. Of the four patients without myocarditis, none was treated with immunosuppressives. Two of these patients improved symptomatically, whereas the conditions of the other two patients deteriorated and heart transplantation was performed for refractory congestive heart failure.
Repeat echocardiograms were performed on all patients 6-8 weeks after initial biopsy ( Table 3 ). The diastolic dimension decreased in the entire group from 6.0±0.2 to 5.2±0.2 (p<0.009), and fractional shortening increased from 17.0±1.9 to 28.1±2.2 (p<0.002). Segregation into patients with and without myocarditis was even more dramatic. Patients with myocarditis demonstrated a decrease in diastolic dimension from 5.9±0.2 to 5.1±0.2 (p<0.02) and increase in fractional shortening from 16.9±1.0 to 29.5±2.3 (p<0.001). The nonmyocarditis group did not experience a significant decrease in diastolic 
(Tx)
Cardiac index (CI; measured by thermodilution) was measured at the time of biopsy. Ejection fraction (EF; measured using nuclear ventriculography) was measured as closely to the time of presentation as possible.
NYHA, New York Heart Association; CHF, congestive heart failure; Tx, cardiac transplantation. dimension or increase in fractional shortening. Repeat right heart catheterization and endomyocardial biopsy was performed on 12 of the 14 patients with myocarditis (biopsy was not repeated in two of four patients with spontaneous recovery). The patients with myocarditis treated with immunosuppressive therapy demonstrated a return of the pulmonary capillary wedge pressure to the normal range and significant improvement in the left ventricular stroke work index (Table 4 ). Follow-up endomyocardial biopsies performed after two months of immunosuppressive therapy demonstrated a resolution of myocyte injury and decrease in the intensity of the inflammatory infiltrate (resolving myocarditis) in all patients studied with concurrent development of mild interstitial or replacement fibrosis in the majority of the patients restudied. Of the four patients with myocarditis who were not treated with immunosuppressives, two consented to repeat endomyocardial biopsy. These biopsies showed near-complete resolution of the myocarditis with the development of mild interstitial and replacement fibrosis (resolving or resolved myocarditis).
All of the patients have been followed for at least 6 months after the development of symptoms. No significant changes have occurred in the conditions of the patients reported, with the exception of one patient without myocarditis who successfully completed another pregnancy. One patient died in our group of 18 patients, and two patients have received cardiac transplantation.
Discussion
Myocarditis has been demonstrated by endomyocardial biopsy in patients with dilated cardiomyopathy and heart failure. [12] [13] [14] [15] [16] incidence of myocarditis in peripartum cardiomyopathy has been reported to be between 29% and 100%.7,17, 18 We have seen myocarditis in 14 of 18 patients (78%) with this disease; several reasons for this apparent discrepancy in the frequency of myocarditis may exist.
Differences in biopsy interpretation and histologic criteria for the diagnosis of myocarditis may be responsible for differences in the incidence of myocarditis.11121516,1 We require the presence of mononuclear cell infiltration associated with myocyte necrosis or degeneration without evidence of cellular hypertrophy or marked fibrosis for the diagnosis of active myocarditis and the presence of a significant mononuclear cell infiltrate without clear-cut myocyte necrosis for borderline myocarditis. These requirements satisfy the diagnosis of myocarditis as established by the Dallas criteria."1 However, lymphocytic infiltration of the myocardium with or without myocyte degeneration is known to be a nonspecific finding in many instances. It has been seen in response to catecholamine release,20 after coronary reperfusion,21 and in response to certain medications.22 Some studies using both biopsy material and human cardiectomy specimens have shown leukocytic infiltration without associated degenerative myocyte changes in as many as 87% of all patients with idiopathic dilated cardiomyopathy.23 The timing of endomyocardial biopsy with respect to the onset of symptoms may result in variation in the intensity of the inflammatory response in myocarditis. Presumably, myocarditis behaves in a manner similar to other inflammatory processes in humans with resolution of mononuclear cell infiltration over time and variability in the amount of fibrosis that develops. '2 The extent to which inflammation clears and the rate at which this process occurs spontaneously is highly variable. O'Connell et a118 and Melvin et a17 reported a high incidence of myocarditis in peripartum cardiomyopathy patients submitted to endomyocardial biopsy within 1 week of the onset of symptoms of congestive heart failure. We have demonstrated that myocarditis may be present on endomyocardial biopsy on average 1 month after the onset of symptoms and for periods of up to 195 days postpartum. We have similarly demonstrated that some residual inflamma- The entire group and those with myocarditis demonstrated a significant improvement in heart size and contractility. Those without myocarditis failed to improve significantly in either category. Values are given in cm. tory infiltrate may be present even after 8 weeks of immunosuppressive therapy despite a significant subjective and objective clinical improvement.
The 14 patients with myocarditis demonstrated a biphasic pattern of presentation. The five patients referred for biopsy within 1 month of delivery all developed abrupt onset severe heart failure and displayed myocarditis by endomyocardial biopsy; four of the five patients improved spontaneously without immunosuppressive therapy. The improvement was rapid, and left ventricular function has remained normal in long-term follow-up. One of these patients was submitted to repeat endomyocardial biopsy 73 days after her first study, and nearly complete resolution of the inflammatory infiltrate was demonstrated. The remaining nine patients with peripartum cardiomyopathy and myocarditis presented more than 50 days postpartum. The onset of symptoms in these patients was more protracted, and initial symptoms are more subtle.
While the natural history of peripartum cardiomyopathy associated with myocarditis is unknown and, despite reports of spontaneous resolution of ventricular dysfunction, we believe that immunosuppressive therapy significantly improved the prognosis of patients with myocarditis. In O'Connell et al's18 series of four patients with peripartum cardiomyopathy and myocarditis, two died and one displayed persistent heart failure symptomatology. In Sanderson et al's17 experience, three of four patients with myocarditis and peripartum cardiomyopathy without immunosuppressive therapy displayed persistent heart failure. There is circumstantial evidence that immunosuppressive therapy reduces myocardial inflammation and improves left ventricular function.7'16,24,25 Melvin et a17 noted a 100% response rate in three patients with peripartum myocarditis and cardiomyopathy, and one of O'Connell et al's18 patients with peripartum myocarditis and cardiomyopathy stabilized with immunosuppressive therapy. In our experience, nine of 10 patients with myocarditis not resolving spontaneously improved dramatically in response to immunosuppressive therapy, not only subjectively but also objectively as demonstrated by echocardiograms and right heart catheterization. Furthermore, these patients demonstrated persistent left ventricular dysfunction despite standard heart failure therapy in the interval between presentation and the initiation of immunosuppressive therapy, implying that spontaneous resolution was unlikely.
The etiology of myocarditis resulting in peripartum cardiomyopathy is not known. It may be viral, drug, toxin, or immune in origin. Spontaneous resolution and variation in the course of the illness from one patient to another may suggest more than one etiology. Postviral myocarditis is believed to be autoimmune in origin.26 Alterations in autoreactive T-cell expression by progesterone may predispose peripartum patients to myocarditis.27 Although the presence or absence of a premonitory history of viral prodrome is nonspecific, none of our patients complained of a preexistant viral illness. We favor an immune as opposed to an infectious etiology. The immune insult is likely related to the pregnancy as the patients have not displayed other immunologic disorders or a relapse of myocarditis after treatment. Fetal allograft acceptance by the mother requires a protective immune response to placental and fetal antigens.28 Maternal antibodies against myometrial proteins or placental or fetal antigens may induce an immunemediated myocarditis with subsequent cardiomyopathy.29 These hypotheses remain speculative until such time as appropriate immunologic studies are performed.
No serious complications were sustained as a result of treatment with immunosuppressive therapy in our patients. One death was noted in a patient who failed to improve with immunosuppressive therapy. This patient was referred to our institution 6 months postpartum with New York Heart Association functional class IV congestive heart failure and an ejection fraction of 8%. This implies that there may be a therapeutic window beyond which immunosuppressive treatment will be ineffective. No patient experienced rebound deterioration in the left ventricular function after discontinuation of immunosuppressive therapy despite a relatively short course of treatment, and no patient developed infection requiring antibiotic therapy. Therefore, therapeutic intervention appears to be useful in some patients and has only limited side effects when administered in the fashion we described.
The present study of 18 patients demonstrates several features of this relatively rare disease. First, the course and prognosis of patients with peripartum cardiomyopathy is highly variable. Second, myocarditis appears to be present in the majority of patients, and we believe that it is the likely etiology. Third, a diagnosis of myocarditis by endomyocardial biopsy does not necessarily require treatment with immunosuppressives if rapid spontaneous resolution occurs. Fourth, immunosuppressive therapy appears to be a safe and effective treatment when peripartum myocarditis and cardiomyopathy is present. Therefore, we recommend endomyocardial biopsy of all patients with peripartum cardiomyopathy and myocarditis who fail to normalize left ventricular function after 1 week of standard medical therapy. We believe immunosuppressive therapy in these patients is justified; however, a prospective double-blind national cooperative trial is indicated to test this hypothesis.
